What 4 Analyst Ratings Have To Say About Ocular Therapeutix

Comments
Loading...

In the latest quarter, 4 analysts provided ratings for Ocular Therapeutix OCUL, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 2 0 0 0
Last 30D 0 1 0 0 0
1M Ago 2 1 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average target is $16.5, accompanied by a high estimate of $19.00 and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.81%.

price target chart

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of Ocular Therapeutix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Luca Issi RBC Capital Announces Outperform $17.00 -
Serge Belanger Needham Announces Buy $15.00 -
Jonathan Wolleben Citizens Capital Markets Lowers Market Outperform $19.00 $22.00
Yi Chen HC Wainwright & Co. Maintains Buy $15.00 $15.00

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ocular Therapeutix. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ocular Therapeutix compared to the broader market.
  • Price Targets: Analysts predict movements in price targets, offering estimates for Ocular Therapeutix's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ocular Therapeutix's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Ocular Therapeutix analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix's Financial Performance

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Ocular Therapeutix's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.41% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Ocular Therapeutix's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -283.27%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.5%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.21%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Ocular Therapeutix's debt-to-equity ratio is below the industry average at 0.24, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

OCUL Logo
OCULOcular Therapeutix Inc
$7.45-6.17%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum27.19
Growth39.40
Quality-
Value22.34
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: